Compare SFHG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | LSTA |
|---|---|---|
| Founded | 1993 | 1980 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 16.4M |
| IPO Year | 2024 | N/A |
| Metric | SFHG | LSTA |
|---|---|---|
| Price | $0.71 | $4.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 81.4K | ★ 320.0K |
| Earning Date | 10-30-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,577,200.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $0.32 | $1.81 |
| 52 Week High | $1.29 | $4.17 |
| Indicator | SFHG | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 90.18 |
| Support Level | $0.65 | $2.05 |
| Resistance Level | $0.78 | $4.17 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.02 | 0.28 |
| Stochastic Oscillator | 25.32 | 93.98 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.